ICLR vs. MRNA: ICON vs. Moderna Stock Comparison

Company Profile

ICON (ICLR) and Moderna (MRNA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while MRNA is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Moderna (MRNA) is heavily traded at around 21.61M shares per day, whereas ICON (ICLR) sees a more moderate 943.50K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile ICON (ICLR) reports 5.26%, ranking against industry peers normally.

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile ICON (ICLR) reports 10.73%, ranking against industry peers normally.

Profitability Metrics

Growth

ICON (ICLR) at 0.76% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both ICON (ICLR) at 1.32 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both ICON (ICLR) at 0.38 and Moderna (MRNA) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither ICON (ICLR) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither ICON (ICLR) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

ICON (ICLR) at 1.86 looks cheap on sales in the lower P/S ratio quartile, while Moderna (MRNA) at 45.55 looks rich in the upper quartile — a clear gap in price per dollar of revenue.

ICON (ICLR) at 1.68 looks cheap against book in the lower P/B ratio quartile, while Moderna (MRNA) at 11.58 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics